Kosin Med J.  2017 Jun;32(1):118-126. 10.7180/kmj.2017.32.1.118.

A Case of Treatment with Steroid and Hydrochloroquine of Thrombocytopenia in Primary Sjögren's Syndrome

• Yun YS
• Choi JW
• Doo YJ
• Kim TH
• Oh HL
• Oh JM

• KMID: 2384841
• DOI: http://doi.org/10.7180/kmj.2017.32.1.118

Abstract

Sjögren's syndrome is a systemic autoimmune disease characterized by sicca symptoms and extraglandular manifestations. Anemia, leukopenia, thrombocytopenia and lymphoproliferative disorders are well-known extraglandular, hematological complications of Sjögren's syndrome. These hematologic alterations are usually mild and respond well with steroid therapy. We report a case of a 52-year-old female patient who was initially presented with thrombocytopenia. The patient was then diagnosed with primary Sjögren's syndrome and initially treated with steroid. The patient's platelet count was decreased when steroid was tapered. The dose of steroid could be effectively reduced after combined medication with hydroxychloroquine.

Keyword

Hydroxychloroquine; Primary Sjögren's syndrome; Steroid; Thrombocytopenia

MeSH Terms

Anemia
Autoimmune Diseases
Female
Humans
Hydroxychloroquine
Leukopenia
Lymphoproliferative Disorders
Middle Aged
Platelet Count
Thrombocytopenia*
Hydroxychloroquine

Figure

• 

  Fig. 1 Contrast-enhanced axial computed tomography shows intraluminal massive pulmonary emboli in both pulmonary arteries (arrow) with multifocal patchy consolidation.

• 

  Fig. 2 Clinical course of this case. Platelet counts were increased significantly with hydroxychloroquine. Prednisolone was successfully tapered.

Reference

1. Jun JW, Bea JK, Lee HS, Kim JH, Ju HW, Choi SW. Treatment with high dose dexamethasone of severe thrombocytopenia in primary Sjögren’s syndrome. J Rheum Dis. 2012; 19:341–343.

2. Bockow B, Kaplan TB. Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports. J Med Case Rep. 2013; 7:91.

3. Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F, et al. Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. J Intern Med. 2015; 278:185–192.

4. Chung WS, Lin CL, Sung FC, Hsu WH, Chen YF, Kao CH. Increased risks of deep vein thrombosis and pulmonary embolism in Sjögren syndrome: a nationwide cohort study. J Rheumatol. 2014; 41:909–915.

5. Asmussen K, Andersen V, Bendixen G, Schiødt M, Oxholm P. A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med. 1996; 239:475–482.

6. Stasi R. How to approach thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2012; 2012:191–197.

7. Choung BS, Yoo WH. Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren's syndrome. Rheumatol Int. 2012; 32:1353–1355.

8. Seo SH, Kim HS, Kwok SK, Ju JH, Kim SH, Yoon CH, et al. Extraglandular manifestations and autoantibodies of korean patients with primary Sjögren's syndrome. J Korean Rheum Assoc. 2007; 14:43–50.

9. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012; 42:145–153.

10. Khellaf M, Chabrol A, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014; 89:194–198.